Stage III NSCLC Patient Outcomes with Induction and Consolidation Immunotherapy, 2018-2022

A retrospective study of 196 patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy before chemoradiotherapy, with or without consolidation immunotherapy. The dataset includes progression-free survival and overall survival outcomes, analyzed using Kaplan–Meier methods and propensity score matching. The study was authored by Jianian Lai and covers patients from four hospitals between February 2018 and December 2022.

Use Cases

• Compare progression-free survival between treatment groups based on consolidation immunotherapy status mentioned in the description
• Analyze overall survival outcomes based on patient cohorts defined by induction and consolidation therapy
• Evaluate the impact of propensity score matching on treatment effect estimates based on the study methodology
• Model survival curves for stage III NSCLC patients based on the reported median follow-up of 24.6 months

Strengths

• Includes data from 196 eligible patients across four hospitals
• Reports specific survival metrics: median PFS of 24.8 months and median OS of 46.0 months for the whole cohort
• Uses propensity score matching to minimize confounding effects, as described in the methodology

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• Data is from a retrospective study, which may reflect inherent selection biases

Provenance

Source

figshare

Collection Method

Multicenter retrospective analysis of patient records

Time Range

February 2018 to December 2022

Freshness

Last updated 2026-04-28 05:27:46; freshness should be verified